According to a market report by Lucintel, the future of the global ocular gene therapy market looks promising with opportunities in the hospitals, diagnostics centers and research institutes markets. The global ocular gene therapy market is expected to grow with a CAGR of 15.1% from 2025 to 2031. The major drivers for this market are the increasing prevalence of ocular diseases and the regulatory approvals & increased investment in R&D.
A more
than 150-page report to understand trends, opportunity and forecast in global ocular
gene therapy market to 2031 by type (gene replacement technology, gene editing
technology, and others), application (hospitals, diagnostics centers, and
research institutes), and region (North America, Europe, Asia Pacific, and the
Rest of the World).
Lucintel
forecasts that, within the type category, gene replacement technology is
expected to witness higher growth over the forecast period due to broader
application & versatility.
Within the
application category, hospital is expected to witness the higher growth due to
high prevalence of ocular diseases.
Download
sample by clicking on ocular gene
therapy market.
In terms
of region, North America is expected to witness the highest growth over the
forecast period.
AbbVie,
MeriaGTx, Regenxbio, GenSight Biologics, Astellas are the major suppliers in
the ocular gene therapy market.
This unique research
report will enable you to make confident business decisions in this globally
competitive marketplace. For a detailed table of contents, contact Lucintel at
+1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost
visit Lucintel's Analytics
Dashboard.
About Lucintel
At Lucintel, we offer solutions for
you growth through game changer ideas and robust market &
unmet needs analysis. We are based in
Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20
years. We are quoted in several publications like the Wall Street Journal,
ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056
Explore Our Latest Publications
No comments:
Post a Comment